Henne Holstege

Has grant

Professor

KU Leuven
Country flagBelgium

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Blood-based markers for Alzheimer’s pathology in cognitively healthy centenarians: revealing mechanisms of resistance and resilience

Open Date: 2021-07-01

Close Date: 2024-06-30

Articles (18)

Body mass index (BMI), type 2 diabetes (T2D) and associated cardiometabolic features modify Alzheimer’s disease (AD) risk, yet shared mechanisms remain poorly understood. Using sex- and age-stratified genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Employing multi-trait, machine learning and single-cell transcriptomics, we identify sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify 35 putative effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping to peripheral immune and metabolic tissues and cell-types. Pathway enrichment identifies druggable targets in calcium and potassium channel signaling. Across 81 approved drugs modulating shared risk genes, levosimendan - a calcium sensitizer for heart failure - inhibits tau oligomerization and emerges as a repurposing candidate. These findings elucidate sex-specific cardiometabolic drivers of AD, identify actionable biological pathways, and reveal drug candidates for AD prevention and treatment.

Year:

2026

Defining the molecular natural history of Alzheimer’s disease (AD) is essential for earlier diagnosis and effective therapeutical interventions. Using longitudinal cerebrospinal fluid proteomics from 191 individuals across the AD spectrum, with up to 15 years of follow-up, we identified protein changes that preceded and tracked with development of amyloid-β (Aβ) and/or p-tau181 abnormality over 2.8–6.1 years. Early alterations included SMOC1 and YWHAZ and were enriched for glycolytic, synaptic, and axonal guidance pathways, which remained consistently altered across advancing disease stages. After Aβ and p-tau181 abnormality, 185 proteins progressively decreased with disease worsening, of which a subset of synaptic and axonal proteins including NPTX2, EPHA10 also tracked cognitive decline. Together, our findings can support clinical trial design through accurate effect size estimates, and enable biomarker guided therapeutic targeting across the full pre-amyloid-to-dementia disease continuum.

Year:

2026

Brains from cognitively intact centenarians offer a unique window into mechanisms of neuroprotection. We quantified 3,448 proteins by LC–MS/MS in middle temporal gyrus (MTG) from 88 Alzheimer’s disease (AD) patients, 53 controls (50–99 years) and 49 centenarians (100+). After adjustment for cell type composition, Aβ abundance associated with only five proteins, revealing upregulation of HTRA1, LRP1 and NRXN1 as early AD-associated changes. Conversely, tau abundance associated with ∼20% of the quantified proteome, revealing GPRIN1 as the top tau-associated protein. One-third of centenarians had high Aβ abundance, often with Braak neurofibrillary tangle stages IV/V, yet all maintained low local tau abundance. Centenarians showed maintained proteostasis (low ubiquitin peptides, high proteasome components), high PCSK1 (prohormone maturation), high PFKFB2 (glycolysis regulation), mitochondria-coupled lipid β-oxidation and lower APOE levels. Together, these findings suggest a model of neuroprotection in which Aβ facilitates tau seeding, and where proteostatic and metabolic adaptations buffer against additional tau accumulation in centenarians.

Year:

2026

The Alzheimer’s disease (AD) genetic landscape identified microglia as a key disease-modifying cell type. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is an immunoreceptor tyrosine–based inhibitory motif domain–containing inhibitory receptor, expressed by myeloid cells such as microglia. The known protective PILRA G78R gene variant reduces AD risk in apolipoprotein E4 ( APOE4 ) carriers and is enriched in a cohort of healthy centenarians. However, mechanisms underlying protective effects in microglia are undefined. Here, we identified biological functions of PILRA in human induced pluripotent stem cell–derived microglia (iMG) and chimeric AD mice. PILRA knockout (KO) in iMG rescued ApoE4-mediated immunometabolic deficits and prevented lipotoxicity through increased lipid storage, improved mitochondrial bioenergetics, and antioxidant activity. PILRA KO also enhanced microglial chemotaxis and attenuated inflammation. With pharmacological inhibitor studies, we showed that peroxisome proliferator–activated receptor and signal transducer and activator of transcription 1/3 mediated PILRA -dependent microglial functions. AD mice transplanted with human PILRA KO microglia exhibited reduced amyloid pathology and rescued synaptic markers. A high-affinity ligand blocking PILRA antibody phenocopied PILRA KO iMG. These findings suggest that PILRA is a pharmacologically tractable therapeutic target for AD.

Year:

2025

Background As part of the retromer, sortilin-related receptor (SORL1) sorts cargo proteins away from the endosome to the trans-Golgi network or to the cell surface, where SORL1 is cleaved into sSORL1 and shed into the interstitial fluid and CSF. SORL1’s cargo includes APP and Aβ, which may explain why protein-truncating genetic variants (PTVs) in SORL1 are observed almost exclusively in Alzheimer’s Disease (AD) patients, and that rare, predicted pathogenic missense variants have been associated with a 10-fold increased risk of AD. However, functional evidence supporting variant pathogenicity is warranted. Here we investigated whether soluble SORL1 (sSORL1) concentrations in cerebrospinal fluid (CSF) offer a potential in vivo biomarker to support impaired SORL1 function in variant carriers. Methods Using an ELISA assay for SORL1 (ABCAM), we determined sSORL1 concentrations in CSF from 218 participants of the Alzheimer Dementia Cohort (ADC) (54% females). We compared sSORL1 in CSF derived from 90 carriers of diverse SORL1 variants with concentrations observed in 78 SORL1 -WT AD patients, and 50 SORL1 -WT controls for whom CSF-pTau-181, CSF-tTau, CSF-Aβ42 concentrations were available. In a subset of 36 individuals, we used Western blotting (WB) to validate sSORL1 concentrations as determined by ELISA. Results CSF-sSORL1 concentrations did not differ between SORL1 -WT AD patients and controls. While CSF-sSORL1 did not correlate with CSF-Aβ42 concentrations in SORL1 -WT AD patients (p=0.62), it correlated with sCSF-ptau-181 (p=9.7×10 −6 ). The mean CSF-sSORL1 concentration in the SORL1 WT AD cases and controls was 466 pg/ml, with wide variance (SD = 133). Comparatively, concentrations were significantly lower in PTV carriers (260 pg/ml, p=3.2×10 −7 ) and in carriers of predicted damaging SORL1 missense variants (323 pg/ml, p=2.4×10 −7 ). CSF-sSORL1 concentrations measured by ELISA correlated strongly with concentrations estimated by WB (ρ=0.552; p=5.0×10 −4 ). Conclusion CSF-sSORL1 increases with CSF-ptau, suggesting that increased SORL1-retromer activity may serve to rescue cellular stress associated with AD-related processes. However, impairing SORL1 genetic variants may preclude SORL1 trafficking to the cell surface, as supported by lower CSF-sSORL1 protein concentrations in carriers. While further refinements are necessary, we present first evidence for the applicability of ELISA-based quantification of sSORL1 in CSF to evaluate the functional impact of rare SORL1 variants.

Year:

2025

We constructed a polygenic protective score specific to Alzheimer’s disease (AD PPS) based on the current literature among the participants enrolled in five studies of healthy aging and extreme longevity in the US, Europe, and Asia. This AD PPS did not include variants on Apolipoprotein E (APOE) gene. Comparisons of AD PPS in different data sets of healthy agers and centenarians showed that centenarians have stronger genetic protection against AD compared to individuals without familial longevity. The current study also shows evidence that this genetic protection increases with increasingly older ages in centenarians (centenarians who died before reaching age 105 years, semi-supercentenarians who reached age 105 to 109 years, and supercentenarians who reached age 110 years and older). However, the genetic protection was of modest size: the average increase in AD PPS was approximately one additional protective allele per 5 years of gained lifetime. Additionally, we show that the higher AD PPS was associated with better cognitive function and decreased mortality. Taken together, this analysis suggests that individuals who achieve the most extreme ages, on average, have the greatest protection against AD. This finding is robust to different genetic backgrounds with important implications for universal applicability of therapeutics that target this AD PPS.

Year:

2025

Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.

Year:

2025

Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.

Year:

2025

We conducted a comprehensive protein quantitative trait loci (pQTL) analysis on a unique set of Gyrus Temporalis Medius (GTM) samples obtained from 88 Alzheimer’s Disease (AD) patients, 53 non-demented individuals, and 49 cognitively healthy centenarians. This investigation revealed 8,081 genetic variants associated with the abundance of 227 proteins, including several novel variant-protein links not identified in a prior pQTL study of the prefrontal cortex or expression QTL (eQTL) analysis across 12 brain regions (GTEx). Among all the AD risk variants tested for possible pQTL effects, only rs429358-T (which encodes the APOE4 allele) was significantly linked to higher APOE levels in the GTM, potentially explaining why this region is particularly prone to AD pathology. Further, through differential correlation analysis we identified AD risk variants linked to altered protein-protein correlations, specifically rs9381040 in TREML2, rs34173062 in SHARPIN, and rs11218343 near SORL1. Notably, DDX17 appears to play a protective role in individuals with the rs9381040-T/T genotype by tightly regulating synuclein levels. Collectively, these findings demonstrate that AD risk variants disrupt protein–protein interactions, highlighting a genetic basis for the coordinated modulation of protein networks in AD.

Year:

2025

Genome-wide association studies (GWAS) linked TMEM106B variants to susceptibility for neurodegenerative diseases, but the causal genetic elements remain unclear. Genotyping of 5,792 Alzheimer disease cases and controls revealed that the TMEM106B locus consists of four major haplotypes: HA/Ha (covering the coding region), and HB/Hb (covering the upstream regulatory region). These combine into four combinations with varying population-frequencies: HAB (57%), HaB (34%), Hab (9%), and HAb (<1%). Long-read sequencing of 513 individuals showed that HA haplotypes (marked by 185-Threonine) carry unique methylated CpG sites and an AluYb8-retrotransposon in the 3’ UTR, while the Ha haplotypes are marked by the 185-Serine allele. Hb haplotypes carry several structural variants (SVs) in nearby distal enhancers, including a 19 Kbp rearrangement, absent in all other haplotypes. Joint association models revealed that the HAB combination (AluYb8+185-Threonine) is risk-increasing, while Hab (SVs+185-Serine) confers the protective effect. HaB (185-Serine only) is neutral, while HAb was too rare to assess. Indeed, relative to middle-aged non-demented controls, cognitively healthy centenarians were more enriched with Hab (OR=1.49, p adj =2.18×10 -2 ) than with HaB (OR=1.23, p adj =5.06×10 -2 ). Finally, proteomic analysis of temporal cortex tissues (n=182) indicated that relative to the neutral HaB combination, the protective Hab is associated with 0.91-fold lower TMEM106B C-terminal peptide abundance (CI=[0.81-1.02]), while the risk-increasing HAB is associated with 1.07-fold higher abundance (CI=[0.99-1.15]). Together, this presents a complex genetic structure underlying the association of the TMEM106B locus with neurodegenerative diseases. ONE SENTENCE SUMMARY GWAS and long-read sequencing suggests that the neurodegenerative genetic etiology associated with TMEM106B is conferred by multiple independent haplotypes.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (105)

Stefanie Heilmann-Heimbach

Head of Laboratory, Research Group Leader

University Hospital Bonn

GERMANY
View details

Ruth Frikke-Schmidt

Professor, Chief Physician, MD PhD DMSc

-

DENMARK
View details

Olivia Belbin

Assistant Professor

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Maria Jesús Bullido Gómez-Heras

Researcher

Universidad Autónoma de Madrid

SPAIN
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

innocenzo rainero

University of Turin

ITALY
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Harro Seelaar

Neurologist

Erasmus MC

NETHERLANDS
View details

Philippe Amouyel

Full Professor

Centre Hospitalier Régional Universitaire de Lille

FRANCE
View details

Jesper Qvist Thomassen

Senior Scientist

Rigshospitalet

DENMARK
View details

Marcel Reinders

Delft University of Technology

NETHERLANDS
View details

Johannes Kornhuber

-

GERMANY
View details

Ruth Loos

The Charles Bronfman Professor in Personalized Medicine

Københavns Universitet

DENMARK
View details

Richard Redon

INSERM

FRANCE
View details

Marco Spallazzi

Adjunt professor

University of Parma

ITALY
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Benedetta Nacmias

University of Florence

ITALY
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Lucilla Parnetti

Professor of Neurology

University of Perugia

ITALY
View details

Caroline Jonson

University of California, San Francisco

UNITED STATES
View details

Pieter Jelle Visser

Karolinska Institutet

SWEDEN
View details

Olav M. Andersen

Aarhus University

DENMARK
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Mieke M. van Haelst

Prof.dr

Amsterdam University Medical Centers

NETHERLANDS
View details

Patrizia Mecocci

Director

Karolinska Institutet

SWEDEN
View details

Mathew Blurton-Jones

Professor

University of California, Irvine

UNITED STATES
View details

Caroline Graff

Professor,MD PhD

Karolinska Institutet

SWEDEN
View details

Henna Martiskainen

University of Eastern Finland

FINLAND
View details

Annemieke J.M. Rozemuller

Professor Neuropathology

-

NETHERLANDS
View details

Amy Kit Yu Fu

Research Professor

The Hong Kong University of Science and Technology

HONG KONG
View details

Arvid Rongve

Professor

University of Bergen

NORWAY
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Betty Tijms

Senior researcher

VU medisch centrum

NETHERLANDS
View details

Martijn Huisman

University of Amsterdam

NETHERLANDS
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

Nancy Yuk-Yu Ip

The Morningside Professor of Life Science

The Hong Kong University of Science and Technology

HONG KONG
View details

Katja Scheffler

Associate Professor

Norwegian University of Science and Technology

NORWAY
View details

Julien Chapuis

Université de Lille

FRANCE
View details

Roos Jutten

Vrije Universiteit Amsterdam

NETHERLANDS
View details

Takeshi Ikeuchi

Professor

Brain Research Institute, Niigata University

JAPAN
View details

Jonathan Vogelgsang

Harvard University

UNITED STATES
View details

Ciyang Wang

Washington University in St. Louis

UNITED STATES
View details

Geir Selbaek

Professor

University of Oslo

NORWAY
View details

Timothy Hohman

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Aarno Palotie

University of Helsinki

FINLAND
View details

Pablo Mir

-

SPAIN
View details

Charlotte Teunissen

University of Amsterdam

NETHERLANDS
View details

Norbert Scherbaum

Professor for Clinical Addiction Research

University of Duisburg-Essen Faculty of Medizin

GERMANY
View details

Tormod Fladby

Professor ll of Neurology

University of Oslo

NORWAY
View details

Margda Waern

University of Gothenburg

SWEDEN
View details

Muhammad Ali

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Lisa Vermunt

Assistant professor

University of Amsterdam

NETHERLANDS
View details

Andrew Saykin

Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center

Indiana University School of Medicine

UNITED STATES
View details

Frank Koopmans

University of Amsterdam

NETHERLANDS
View details

Erik A. Sistermans

-

NETHERLANDS
View details

Srdjan Djurovic

Professor at University of Oslo

University of Oslo

NORWAY
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Najaf Amin

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

Peter Holmans

Professor of Biostatistics and Genetic Epidemiology

Cardiff University

UNITED KINGDOM
View details

Hayk Davtyan

Reserach Professor

University of California, Irvine

UNITED STATES
View details

David M. Holtzman

Washington University School of Medicine

UNITED STATES
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Alessio Squassina

Dalhousie University

CANADA
View details

Carole Dufouil

Director of research

INSERM

FRANCE
View details

Virginia M-Y Lee

Professor

University of Pennsylvania

UNITED STATES
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Martin Ingelsson

Specialist

Uppsala University Hospital

SWEDEN
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

María José Romero Lado

University of Copenhagen

DENMARK
View details

Gael Nicolas

PUPH

University of Rouen

FRANCE
View details

Shahzad Ahmad

Staff Scientist

University of Oxford

UNITED KINGDOM
View details

Riccardo E Marioni

University of Edinburgh

UNITED KINGDOM
View details

Devrim Kilinc

Institut Pasteur de Lille

FRANCE
View details

Anssi Lipponen

University of Eastern Finland

FINLAND
View details

Avishek Roy

Karolinska Institutet

SWEDEN
View details

Patrick Kehoe

Academic , Gestetner Professor of Translational Dementia Research

University of Bristol

UNITED KINGDOM
View details

Alison Goate

Professor and Chair

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

INGVILD SALTVEDT

Professor

Norwegian University of Science and Technology

NORWAY
View details

Jean Paul Chadarevian

University of California, Irvine

UNITED STATES
View details

Dag Aarsland

Professor and Head of Department

King’s College London

UNITED KINGDOM
View details

Yolande A.L. Pijnenburg

-

NETHERLANDS
View details

Daniela Galimberti

Associate Professor

Università degli Studi di Torino

ITALY
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Ole A. Andreassen

Oslo University Hospital

NORWAY
View details

Lucio Tremolizzo

Associate Professor of Neurology

University of Milano-Bicocca

ITALY
View details

Suzanne Miedema

University of Amsterdam

NETHERLANDS
View details

Valentina Escott-Price

Professor

Cardiff University

UNITED KINGDOM
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Simon Mead

Deputy Director

University College London

UNITED KINGDOM
View details

Barbara Borroni

Docenti di ruolo di IIa fascia

University of Brescia

ITALY
View details

Florence Pasquier

Professor

Université de Lille

FRANCE
View details

Lars Bertram

Professor of Genome Analytics

University of Lübeck

GERMANY
View details

Jose Luis Royo

University of Malaga

SPAIN
View details

Mikko Hiltunen

University of Eastern Finland

FINLAND
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Alberto Lleó

Director

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Sterling Johnson

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menghan Liu

Washington University in St. Louis

UNITED STATES
View details

Tuomas Kilpeläinen

Assistant professor

Københavns Universitet

DENMARK
View details